This article is more than 5 years old. Information may no longer be current.

Alimera reports revenue increase in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences reported a global revenue increase of 66% and U.S. revenue increase of 89% in the second quarter compared with the same period a year ago, according to a press release.

Consolidated net revenue increased to approximately $9.6 million in the second quarter compared with $5.8 million in the second quarter of 2015.

U.S. net revenue increased by approximately $3.4 million to approximately $7.2 million, which was attributed to higher sales volume of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg). International net revenue increased by approximately $300,000 to approximately $2.3 million.

Quarterly GAAP net loss was $6.9 million, or $0.15 per share, compared with a net loss of $8.6 million, or $0.19 per share, a year ago

Consolidated research, development and medical affairs expenses were $3.2 million, compared with $3.8 million a year ago, due to lower spending on post-marketing studies of Iluvien.